NCT05127811终止1 期
A Phase I Dose Escalation Study of ZN-d5 Monotherapy in Chinese Subjects With Non-Hodgkin Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 8
- 试验地点
- 3
- 主要终点
- Safety monitoring
研究概览
简要总结
A phase I dose-escalation, open-label, multicenter study to assess the safety, tolerability, clinical activity, and pharmacokinetics (PK) of ZN-d5 in Chinese subjects with non-Hodgkin lymphoma (NHL).
详细描述
For the Phase I dose escalation study of ZN-d5, it is planned that after the starting dose, subsequent dose assignments will be made by means of a model-assisted design, until the MTD or RP2D is determined in the Chinese population.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •NHL, relapsed from or refractory to at least 2 prior lines of systemic therapy (excluding radiotherapy and surgery); subjects must have failed or not be candidates for available standard therapy expected to provide clinical benefit.
- •Female subjects of childbearing potential must have a negative serum pregnancy test and agree to use contraception while on study.
- •Eastern Cooperative Oncology Group performance status ≤
- •Adequate blood and other organ function, defined by the following criteria:
- •Neutrophil count (ANC) ≥ 1.0 × 109/L.
- •Platelet count ≥ 75 × 109/L at least 3 days after platelet transfusion (≥ 50 × 109/L permitted if the bone marrow is > 50% lymphoma cells).
- •Hemoglobin ≥ 8.0 g/dL.
- •Coagulation parameters ≤ 1.5 × upper limit of normal (ULN).
- •Liver enzymes ≤ 3 × ULN and total bilirubin ≤ 1.5 × ULN.
- •Creatinine clearance ≥ 60 mL/min.
排除标准
- •Received any of the following prior to start of ZN-d5 treatment:
- •Systemic administration of antineoplastic agents (including investigational agents) within the shorter of 28 days or 5 half-lives.
- •Major surgery within 28 days.
- •Radiotherapy within 14 days.
- •Autologous or allogeneic stem cell transplantation within 60 days, or receiving immunosuppression for active graft-versus-host disease.
- •Use of strong CYP3A4 inhibitors, P-gp inhibitors or QT prolonging agents within 5 half-lives, or potent or moderate CYP3A4 inducers within 14 days.
- •Ongoing and clinically significant non-hematologic toxicity related to prior antineoplastic therapy.
- •Presence of major cardiovascular system diseases (including QTcF > 480 msec).
- •Positive serology for human immunodeficiency virus, hepatitis B, or hepatitis C unless no detectable hepatitis B or C viral load.
- •Unable to take oral drugs or presence of severe gastrointestinal abnormalities.
- •Active and uncontrolled clinically significant infection.
- •Other active systemic malignancy or other severe, unstable, or poorly controlled acute or chronic medical conditions.
- •Prior treatment with venetoclax or other BCL-2 inhibitors.
- •Primary or secondary CNS lymphoma.
- •Presence of post-transplant lymphoproliferative disease, Burkitt's lymphoma, Burkitt-like lymphoma, T lymphoblastic lymphoma and T lymphoblastic acute leukemia.
研究组 & 干预措施
400mg(on empty)
Experimental
干预措施: ZN-d5 (Drug)
100mg(on empty)
Experimental
干预措施: ZN-d5 (Drug)
200mg(on empty)
Experimental
干预措施: ZN-d5 (Drug)
600mg(on empty)
Experimental
干预措施: ZN-d5 (Drug)
600mg（with a meal）
Experimental
干预措施: ZN-d5 (Drug)
800mg(with a meal)
Experimental
干预措施: ZN-d5 (Drug)
结局指标
主要结局
Safety monitoring
时间窗: until 30 days after the last dose of study drug
Incidence and severity of adverse events (AEs), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0
DLT
时间窗: at the end of Cycle 1
Dose-limiting toxicities (DLTs) observed in DLT evaluable subjects
次要结局
- Maximum Plasma Concentration [Cmax](up to 24 months)
- Effacy Evaluation(up to 24 months)
研究者
研究点 (3)
Loading locations...
相似试验
招募中
1 期
A Study of SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C MutationAdvanced Solid TumorNCT06006793Shouyao Holdings (Beijing) Co. LTD50
已完成
1 期
A Study of ZN-c5 and Abemaciclib in Participants With Breast CancerBreast CancerNCT04514159Zeno Alpha Inc.14
终止
1 期
M3541 in Combination With Radiotherapy in Solid TumorsSolid TumorsNCT03225105EMD Serono Research & Development Institute, Inc.15
终止
1 期
A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.Solid TumourAdvanced Solid MalignanciesChild-Pugh A to B7 Advanced Hepatocellular CarcinomaEGFR and/or ROS Mutant NSCLCLung Metastasis CarcinomaGastric CancerNCT01219543AstraZeneca47
尚未招募
1 期
A Study of Mitoxantrone Hydrochloride Liposome Injection Combination Therapy in Chinese Patients With Advanced Solid TumorsAdvanced Solid TumorNCT05344742CSPC ZhongQi Pharmaceutical Technology Co., Ltd.116